Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Efineptakin alfa by NeoImmuneTech for Colorectal Cancer: Likelihood of Approval
Efineptakin alfa is under clinical development by NeoImmuneTech and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...
Efineptakin alfa by NeoImmuneTech for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Efineptakin alfa is under clinical development by NeoImmuneTech and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
Efineptakin alfa by NeoImmuneTech for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Efineptakin alfa is under clinical development by NeoImmuneTech and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
Efineptakin alfa by Genexine for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
Efineptakin alfa is under clinical development by Genexine and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to...
Efineptakin alfa by NeoImmuneTech for Solid Tumor: Likelihood of Approval
Efineptakin alfa is under clinical development by NeoImmuneTech and currently in Phase II for Solid Tumor. According to GlobalData, Phase...